Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02817750
Recruitment Status : Completed
First Posted : June 29, 2016
Last Update Posted : June 11, 2018
Sponsor:
Information provided by (Responsible Party):
Biolab Sanus Farmaceutica

Brief Summary:
The purpose of this study is to evaluate the pharmacokinetics of the new formulation of zolpidem hemitartarate orodispersible tablet 3.5 mg in male and female healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial) Drug: zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting) Phase 1

Detailed Description:

This is a phase I study of zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and postprandial administration. Sample size is 28 volunteers, male and female, aged from 18 to 50 years old.

This is an open-label, randomized, crossover study. Each volunteer will be randomized to one of the following sequencies:

  • Sequency 1: zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting (period 1) and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial (period 2)
  • Sequency 2: zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial (period 1) and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting (period 2) Formulation will be administered in a single dose, orally in each period. The volunteers will be admitted in two different periods of 36 hours each, when investigational product will be administered and blood samples will be collected at pre-determined periods of time up to 24 hours for pharmacokinetics evaluation.

Primary objective is to evaluate the pharmacokinetics of the new formulation of zolpidem hemitartarate orodispersible tablet 3.5 mg in healthy volunteers. As a secondary objective, it will be evaluated if there is any pharmacokinetics difference between genders.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus Farmacêutica Ltda
Actual Study Start Date : July 5, 2017
Actual Primary Completion Date : February 22, 2018
Actual Study Completion Date : February 22, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: zolpidem hemitartarate (fasting + post-prandial)
zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
Drug: zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)
zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial

Experimental: zolpidem hemitartarate (post-prandial + fasting)
zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
Drug: zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)
zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting




Primary Outcome Measures :
  1. Area under the curve (0-last) [ Time Frame: 24 hours ]
  2. Area under the curve (0-inf) [ Time Frame: 24 hours ]
  3. Half life (t1/2) [ Time Frame: 24 hours ]
  4. Elimination rate constant (Ke) [ Time Frame: 24 hours ]
  5. Maximum serum concentration (Cmax) [ Time Frame: 24 hours ]
  6. Time to reach maximum (peak) plasma concentration following drug administration (tmax) [ Time Frame: 24 hours ]
  7. Volume of distribution (Vd) [ Time Frame: 24 hours ]
  8. Clearance (C) [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Number of adverse events [ Time Frame: 60 days ]
  2. Intensity of adverse events [ Time Frame: 60 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female volunteers, aged from 18 to 50 years old (women cannot be pregnant or in breastfeeding period and should be committed to use an effective contraceptive method during the study)
  • Body mass index (BMI) greater than or equal to 18.5 and less than or equal to 29.9 kg/m2
  • Good health conditions or without significant diseases, according to best medical judgment, according to medical history, blood pressure and heart rate measurements, pulse, temperature, physical examination, electrocardiogram (ECG) and complementary laboratory tests
  • Ability to understand the nature and objectives of the trial, including risks and adverse events, willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by informed consent form signature.

Exclusion Criteria:

  • Know hypersensitivity to the investigational product (Zolpidem) or chemically related compounds
  • History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism
  • Maintenance therapy with any drugs, except oral contraceptives
  • History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic, psychiatric, cardiologic or allergic diseases of any etiology , that requires pharmacological treatment or considered as clinically relevant by the investigator
  • Electrocardiographic findings that at investigator discretion are not recommended for study participation
  • Deviations on screening laboratory results that are considered as clinically relevant by the investigator
  • Smoking
  • Intake of more than five cups of coffee or tea per day
  • History of abusive use of drugs and alcohol
  • Use of regular medication two weeks prior to study enrollment or use of any medications one week prior to study enrollment
  • Hospitalization for any reasons up to 8 weeks prior to start of first period of trial treatment
  • Treatment within 3 months prior to the start of trial treatment, with any drug with known and well-established toxic potential to major organs
  • Participation in any pharmacokinetics trial with more than 300 mL of blood draw or administration of any experimental drug within 12 months prior to trial treatment start
  • Donation or loss of 450 mL or more of blood within 3 months prior to trial enrollment or donation of more than 1500 mL of blood within 12 months prior to the trial treatment start
  • Positive result for the BHCG urine test, performed by female subjects
  • Positive results for the detection of abusive drugs at urine exam
  • Result higher than 0.1 mg/L for the etilometer exam
  • Any condition, according to investigator's best judgment, that prevents the subject to participate in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02817750


Locations
Layout table for location information
Brazil
UNIFAG - Unidade Integrada de Farmacologia e Gastroenterologia
Bragança Paulista, SP, Brazil, 12916-900
Sponsors and Collaborators
Biolab Sanus Farmaceutica
Investigators
Layout table for investigator information
Principal Investigator: José Pedrazzoli Júnior, PhD UNIFAG - Universidade Integrada de Farmacologia e Gastroenterologia

Layout table for additonal information
Responsible Party: Biolab Sanus Farmaceutica
ClinicalTrials.gov Identifier: NCT02817750     History of Changes
Other Study ID Numbers: JPJ 16/16
First Posted: June 29, 2016    Key Record Dates
Last Update Posted: June 11, 2018
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Biolab Sanus Farmaceutica:
volunteers
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Zolpidem
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action